Evidence map›Paper›PMID 39037274›Full record

ArticleAntimicrobial agents and chemotherapy2024

Case Commentary: Extending our therapeutic range against multidrug-resistant

Max W Adelman, David R Andes

Abstract readComment
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Max W AdelmanDivision of Infectious Diseases, Department of Medicine, Houston Methodist Hospital, Houston, Texas, USA.ORCID 0000-0002-9277-6046
David R AndesDivision of Infectious Diseases, Department of Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA.ORCID 0000-0002-7927-9950

Funding

Pathogen and patient determinants of Candida gut colonization in critically ill patientsK23AI185174 · NIAID · METHODIST HOSPITAL RESEARCH INSTITUTE · PI Max Wiener Adelman · 2024 to 2026
$582k
HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) K23AI185174Houston Methodist Hospital | Houston Methodist Research Institute (HMRI) Clinical Scholars AwardNIAID NIH HHS K23 AI185174
6 · The paper itself

Abstract

Deep-seated

Indexed as

Antifungal AgentsCandidaDrug Resistance, Multiple, FungalEchinocandinsCandidiasisHumansMicrobial Sensitivity TestsAntifungal AgentsEchinocandinsRezafunginantifungal agentsantifungal resistanceantifungal therapyCandidaendocarditisosteomyelitis

Identifiers

PMID39037274
PMCPMC11304684

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.